Q1 2023 Results
Company overview
Financial review
Conclusions
Appendix
References
Millburn approved for PluvictoⓇ commercial supply in US;
Zaragoza approved for EU
GROWTH
Expected commercial coverage by end 2023
Manufacturing site:
Ivrea
Millburn
Indianapolis
Zaragoza
US
✓ Approved
✓ Approved
FDA filing in
preparation
EU
✓ Approved
ROW
✓ Approved 1
✓ Approved²
✓ Approved
In preparation²
In preparation
P
PLUVICTO™
Millburn to ramp up gradually; expected to contribute meaningfully to supply and sales in Q3 after anticipated approval of additional lines
Ivrea will continue to supply the US market in addition to EU
Zaragoza also approved to supply EU
Targeting capacity of at least 250k doses annually for 2024+3
1. Currently approved for Canada, Switzerland and UK; further ROW submissions ongoing. 2. Canada. 3. Total production across all RLTS.
19 Investor Relations | Q1 2023 Results
NOVARTIS | Reimagining MedicineView entire presentation